At a glance
- Originator Pfizer
- Class Antihyperlipidaemics; Small molecules
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 20 Jul 1998 No-Development-Reported for Hypercholesterolaemia in USA (Unknown route)
- 12 Jul 1995 Preclinical development for Hypercholesterolaemia in USA (Unknown route)